US Pharm. 2012;37(8):54.
Prodigy Health Supplier entered a joint venture with Stason Pharmaceuticals to bring a diverse line of quality generic pharmaceuticals to the U.S. market. The partnership supports robust research and development, with 30 PhDs on staff and over 120 people in that department. Core generic therapeutic categories include oncologic, central nervous system, cardiovascular, and dermatologic indications. Delivery mechanisms for the drugs include capsules and oral solids as well as new delivery mechanisms. Bryan Sanders, president of Prodigy Health Supplier, states, “Three of our current registrations are found on the national FDA shortage list and we are dedicated to bringing these products to market as soon as possible to help alleviate this strain. There are seven drugs in our present pipeline that will be released over the next 2 years and we are evaluating additional items on the shortage list for potential registration and production.”